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Aims Diagnosis of heart failure in older people in long-term care is challenging because of co-morbidities, cognitive deficit,
polypharmacy, immobility, and poor access to services. This study aimed to ascertain heart failure prevalence and
clinical management in this population.
Methods
and results
A total of 405 residents, aged 65–100 years, in 33 UK care facilities were prospectively enrolled between April 2009
and June 2010. The presence of heart failure was determined using European Society of Cardiology guidelines, modi-
fied where necessary for immobility. Evaluation of symptoms and signs, functional capacity, and quality of life, portable
on-site echocardiography, and medical record review were completed in 399 cases. The point prevalence of heart
failure was 22.8% [n ¼ 91, 95% confidence interval (CI) 18.8–27.2%]; of these, 62.7% (n ¼ 57, 95% CI 59.6–
66.5%) had heart failure with preserved ejection fraction and 37.3% had left ventricular systolic dysfunction
(n ¼ 34, 95% CI 34.8–40.5%). A total of 76% (n ¼ 61) of previous diagnoses of heart failure were not confirmed,
and up to 90% (n ¼ 82) of study cases were new. No symptoms or signs were reliable predictors of heart failure.
Conclusion Heart failure was diagnosed in almost a quarter of residents: the prevalence was substantially higher than in other popu-
lations. The majority of heart failure cases were undiagnosed, while three-quarters of previously recorded cases were
misdiagnosed. Common symptoms and signs appear to have little clinical utility in this population. Early, accurate dif-
ferential diagnosis is key to the effective management of heart failure; this may be failing in long-term care facilities.
Trial
registration
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Keywords Heart failure with preserved ejection fraction (HFpEF) † Diagnosis † Prevalence † Older people † Long-term care
Introduction
Heart failure (HF) has a progressive, negative impact upon quality
of life, morbidity, and mortality, which may be improved substan-
tially by accurate diagnosis and management. Although the
prevalence of HF is highest in older people, 1 diagnosis and man-
agement are likely to be least comprehensive in long-term
care.2 –5 In this setting, where access to health services may be
limited, acute care often takes precedence over chronic care and
preventative needs.6 In practice, HF symptoms are often non-
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specific, physical signs may be difficult to elicit,7 – 12 and, for
unknown reasons, the prevalence of cardiovascular co-morbidities
may be lower in older people.13 As long-term care residents are
often unable to attend outside clinics or diagnostic facilities, the
lack of availability of echocardiography in this setting further com-
plicates diagnosis and management.14– 17 Internationally, the most
relevant studies suggest a prevalence of 10–42% in long-term
care,9,18,19 6.7% in the general population,20 and 46% in older
people presenting to hospital with HF symptoms.11 While data
on undiagnosed HF are inherently difficult to obtain, current evi-
dence suggests that an accurate diagnosis may be missed in up
to half of cases.18,21–24 Despite the higher prevalence of HF in
older people, there is a paucity of research that examines either
assessment and diagnostic practices or care provision for this de-
bilitating disease. The relative prevalence of HF with reduced ejec-
tion fraction [left ventricular systolic dysfunction (LVSD) or HFrEF]
and preserved ejection fraction (HFpEF) is unknown, though
HFpEF may account for. 50% of HF hospitalizations in the
elderly.25–28 The aim of this study was to establish the overall
prevalence of HF (and by type) in long-term care facilities using
on-site echocardiography and a review of treatment for existing
diagnoses of HF.
Methods
Study population
Residents from long-term care facilities (UK residential and nursing
homes) in Teesside, North East England, aged ≥65 years without ter-
minal disease and who were permanently resident were eligible to par-
ticipate. Study data were collected over a 14-month period from April
2009. Initial and process consent was sought directly from the resident,
or from their relative (or a consultee) when a resident lacked the cap-
acity to provide informed consent. Capacity to consent was deter-
mined by the Mini Mental State Examination (MMSE)29 and process
consent using the abbreviated mental tests score (AMTS)30 prior to
assessments. Anonymized demographic details (date of birth, gender,
and ethnicity) of all eligible residents (including non-participants)
were extracted.
Investigation
Participants underwent a diagnostic assessment within each facility,
including MMSE,29 demographic information, medication, and past
medical history, quality of life assessment (EuroQol: EQ-5D and
EQ-VAS),31 physical examination, electrocardiography, echocardiog-
raphy,32 and blood sampling. Portable echocardiograms (Vivid-i, appli-
cation software version 6.2.0, system software 2.1.16, 3RS probe) were
performed by a British Society of Echocardiography (BSE)-accredited
physiologist according to European Society of Cardiology (ESC) guide-
lines,19,25 and electrocardiograms (ECGs; GE MAC 1600, cardiosoft
version 6.5) by a trained technician. Full echocardiograms, including
colour Doppler, were performed, and images were stored for
off-line assessment. Linear and M-mode cardiac chamber measure-
ments were obtained from the parasternal long and short axis view
in accordance with American Society of Cardiology (ASC) recommen-
dations.33 All assessments were conducted by the study team; echo-
cardiography, ECG, and physical assessment findings were blinded
from each other; findings were reviewed by a consultant cardiologist
(J.J.M.) who made the definitive diagnosis of HF (LVSD or HFpEF).
Findings were subsequently reviewed by a second HF specialist (A.F.)
who was blinded to the diagnosis (with 100% agreement). On comple-
tion of the study 12.5% (50) of echocardiograms were randomly
selected and independently reported by a BSE-accredited cardiac
physiologist (not involved in the study) to test the reliability and valid-
ity of the findings (with 100% agreement for significant left ventricular
dysfunction and valve disease).
Differential definitions of heart failure
Definitions of HF were based on ESC guidelines available at the time of
the study,19,25 modified for the potential impact of both cognitive im-
pairment and immobility resulting from co-morbidities. Symptoms and
signs compatible with HF were defined as: (i) breathlessness, graded as
New York Heart Association (NYHA) class II, III, or IV; (ii) moderate
oedema (up to the knees bilaterally); or (iii) mild oedema (confined to
the ankles) + one other clinical sign (see below); (iv) mild oedema and
taking at least furosemide 40 mg (or equivalent) per day; or (v) two or
more other signs [raised jugular venous pressure (JVP), lung crackles,
respiratory rate .20/min, third heart sound].
Left ventricular systolic dysfunction was assessed: using the ‘eyeball’
method as normal, or mildly, moderately, or severely impaired; by left
ventricular ejection fraction (LVEF) calculated by Simpson’s rule; and
by wall motion index using the ASC recommendations.33 Doppler
and tissue Doppler measurements of the longitudinal function of the
heart were used to determine left ventricular diastolic dysfunction
(LVDD). Measurements of the ratio of early transmitral flow velocity
and early mitral annular velocity (E/E’) were recorded at both the
septum and lateral wall.
All residents with clinical features and either an LVEF of ≤50% or
whose left ventricular systolic function was assessed by ‘eyeball’ to
be mildly, moderately, or severely impaired were classified as having
HF due to LVSD. HFpEF was diagnosed in accordance with ESC guide-
lines19 using clinical, echocardiographic, and brain natriuretic peptide
(BNP) measurements. Patients with clinical features of HF whose
LVEF was .50% with an E/E’ .15, or those with an equivocal E/E’
(8–15) but BNP .200 pg/mL or N-terminal proBNP (NT-proBNP)
.220 pg/mL were diagnosed as having HFpEF.
Study endpoints
Point prevalence was measured according to the clinical diagnosis of
HF, and differentiated as LVSD, LVSD-HF, or HFpEF. Symptom and
sign profiles (including MMSE, AMTS, and NYHA class), co-morbidities
and prescribed medications, quality of life (EQ-5D and EQ-VAS),31 and
characteristics of care provision and diagnostic agreement in general
practice and care facility records were reported for those with and
without HF.
Data analysis
All calculations were performed using SPSS version 19. Continuous
data are expressed as mean, range, and standard deviation (SD)
(unless otherwise stated) and binary data as proportions. A value of
P, 0.05 was considered significant for the purpose of hypothesis gen-
eration. Comparisons between groups were made using Student’s
t-test for continuous data and Fisher’s exact test for proportions. Resi-
dents with incomplete echocardiographic assessment were excluded
from the analysis.
Ethical approval
The study protocol received prior local research management and
governance and national ethics approvals, and the study complies
with the Declaration of Helsinki. Informed consent was obtained
from all subjects or guardians.
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Results
Study population
Thirty-three care facilities (with a total of 1701 beds) agreed to
participate in the study; two declined. Study participants were
registered with 23 general practices (including 93 primary care
physicians).
Data were collected on non-participating residents; 529 resi-
dents (of the total 1701) were judged by care facility managers
to be ineligible predominantly due to concerns over the balance
of risks and benefits of participating. Of the remaining 1172 eligible
residents, consent for participation was obtained for 405 (35%).
The primary reason for non-participation was relatives declining
on behalf of residents due to similar concerns. Portable echocardi-
ography was not possible in six participants; 399 participants with
complete data are reported.
Participant age ranged from 65 to 100 years (mean 84 years); the
majority (54%) were ≥85 years. Participants were almost exclu-
sively white British (99%) and the majority were female (74%). Eli-
gible non-participants and participants showed similar baseline
demographic characteristics (see Table 1), demonstrating no dis-
crimination on the basis of age, gender, or ethnicity. Baseline char-
acteristics of participants are shown in Table 2.
Study diagnosis
The point prevalence of HF was 22.8% [n ¼ 91, 95% confidence
interval (CI) 18.8–27.2%]; of these, 62.7% (n ¼ 57, 95% CI
59.6–66.5%) had HFpEF and 37.3% had LVSD (n ¼ 34, 95% CI
34.8–40.5%). A further three patients had LVSD without clinical
signs of HF. In total, 34 (8.5%, 95% CI 6.0–11.7%) were diagnosed
with LVSD, categorized as: mild, 19 (56%); moderate, 9 (27%); or
severe, 6 (18%). Participants with and without LVSD were broadly
similar in terms of age and sex (Table 2).
Participants with LVSD were more likely to have orthopnoea, a
raised JVP, lung crackles, abnormal ECG, and mitral regurgitation
(see Table 3 for a complete list of clinical symptoms and signs).
HFpEF additionally featured raised levels of peripheral oedema.
The number qualifying for HFpEF according to ESC criteria19 of
E/E’ (8–15) and BNP .200 pg/mL (or NT-proBNP .220 pg/mL)
was 11 residents (19%); the remainder (n ¼ 46) had an E/E’ of .15.
The NYHA classification was not a reliable indicator of systolic
dysfunction; participants with an assessment of NYHA class IV
were classified as having mild or moderate LVSD, while those
with NYHA class I had mild, moderate, or severe LVSD. Study as-
sessment of NYHA classification was not possible in 101 partici-
pants (25%) due to immobility; the remainder were ambulant. A
total of 129 (32%) residents had an elevated respiratory rate
(.20 breaths/min), and 183 (49%) had peripheral oedema (mild
or moderate); 59 (15%) residents had both, and, of these, four resi-
dents also had a raised BNP (.400 pg/mL). Of the 59 symptomatic
residents with an elevated respiratory rate and peripheral oedema,
20 (34%) had HF, of which 5 had an existing record of HF and15
were newly diagnosed. Of the four residents with these signs
plus a raised BNP, three had HF, of which one was newly
diagnosed.
The acceptability of the diagnostic assessment by residents was
high: four (1%) residents reported they would decline a request to
repeat parts of the assessments, two found the echocardiogram
procedure uncomfortable, and two reported they would decline
further blood tests. There were only four unsuccessful venepunc-
ture attempts in the 405 participants.
Comparison of study and recorded
diagnoses
Medical records did not specify the type or severity of HF in 99%
of cases. Up to 50% of confirmed LVSD was previously diagnosed
and noted in primary care, but only 12% was recorded in care fa-
cility notes. HFpEF was previously undiagnosed in  90% of cases
(Table 4). Of 71 cases recorded either in general practice notes or
in a HF register, 17 (24%) were confirmed as either LVSD or HFpEF.
Study diagnosis, recorded co-morbidity,
and clinical care
According to general practice records, the three most common
co-morbidities were hypertension (48%), osteoarthritis (36%),
and cognitive impairment (30%) (Table 5). Only eight (2%) partici-
pants had no record of any co-morbidity; none of these had HF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Care facility residents: comparison of participants and non-participants
Characteristics Participants (n 5 399) Non-participants (n 5 767)
Age (years) 65–74 46 (11.5%) 83 (10.8%)
75–84 136 (34.1%) 294 (38.3%)
85+ 217 (54.4%) 390 (50.8%)
Mean (SD, range) 84.2 (7.2, 65–100) 84.5 (7.6, 65–106)
Gender Male 105 (26.3%) 198 (25.8%)
Female 294 (73.7%) 569 (74.1%)
Ethnicity White British 393 (98.5%) 767 (100%)
White European 6 (1.5%) 0 (0%)
Other 0 (0%) 0 (0%)
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Participants had a mean of three co-morbidities (range 1–7, SD
1.4) (Table 5). The number of co-morbidities was not significantly
different between those with and without HF (P ¼ 0.641). Partici-
pants with LVSD were more likely to have a previous myocardial
infarction or atrial fibrillation and to have been prescribed beta-
blockers, angiotensin-converting enzyme (ACE) inhibitors, diuretics,
and warfarin (Table 5). Nearly 50% of these patients were receiving
an ACE inhibitor or beta-blocker. Of 80 patients with any pre-
existing record of HF, 36% were receiving an ACE inhibitor and
43% beta-blockers (Table 6).
Discussion
In our large, institution-based study of older people, we report that
HF was diagnosed in almost a quarter of residents, two-thirds of
whom had HFpEF. The prevalence of HF was substantially higher
than in community populations. Most cases of HF were previously
undiagnosed, and three-quarters of previously recorded cases
were not confirmed. Symptoms and signs typically associated
with HF such as leg oedema and breathlesness appear to have
little clinical utility in this population. In summary, these findings
indicate a HF and HFpEF burden that is substantially higher than
previously thought.
Previous studies
Four studies have previously estimated the prevalence of HF in
long-term care, varying from 23% to 42%.18,24,34,35 These studies
were small (100–150 residents), with the exception of one large
US study (nearly 3000 residents).28 Participants’ mean age and
gender distributions were similar to those of the cohort in this
study, but definitions of HF and methods of diagnosis varied.
Most studies relied on medical records to identify HF, with no
details about operational definitions; only one prevalence study16
used echocardiography to assess and define the presence of
LVSD. For comparison, the prevalence of undifferentiated HF
based on medical records (a HF register) in our study was 32%.
Recent evidence suggests potential prognostic benefits of ACE
inhibitors for patients with HFpEF.36 However, findings from this
study indicate a tendency towards the use of diuretics for this
group. The high incidence of HFpEF detected suggests the need
for further research in this population, in order to establish clear
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Characteristics of participants by (study-determined) heart failure status
Characteristics No HF (A), n5 308 LVSD (B), n 534
(%)a
HFpEF (C), n5 57 P-value
(A vs. B)
P-value
(A vs. C)
Age (years) 65–74 42 (13.6%) 4 (11.8%) 0 (0%) 0.829g 0.004g
75–84 109 (35.4%) 10 (29.4%) 17 (29.8%)
85+ 157 (51.0%) 20 (58.8%) 40 (70.2%)
Meanb 83.5 (7.3, 65–99) 84.3 (6.6, 70–98) 87.6 (5.6, 75–100)
Gender Male 82 (26.6%) 13 (38.2%) 10 (17.5%) 0.077 0.068
Female 226 (73.4%) 21 (61.8%) 47 (82.5%)
Ethnicity White British 303 (98.4%) 34 (100%) 56 (98.2%) 0.584g 0.606g
White European 5 (1.6%) 0 (0%) 1 (1.8%)
Care facility typec Nursing 94 (30.5%) 9 (26.5%) 17 (29.8%) 0.314g 0.635g
Residential 202 (65.6%) 22 (64.7%) 39 (68.4%)
Dementia 12 (3.9%) 3 (8.8%) 1 (1.8%)
MMSE scored 0 36 (11.7%) 4 (11.8%) 5 (8.8%) 0.358g 0.746g
1–23 174 (56.5%) 15 (44.1%) 31 (54.4%)
≥24 98 (31.8%) 15 (44.1%) 21 (36.8%)
MMSE description Alert 287 (93.2) 34 (100%) 54 (94.7%) 0.304g 0.905g
Drowsy 20 (6.5%) 0 (0%) 3 (5.3%)
Coma 1 (0.3%) 0 (0%) 0 (0%)
BMIe Meanb 25.5 (5.4, 11–45) 26.2 (4.8, 18–36) 25.3 (4.6, 17–35) 0.535 0.961
EQ-5D Meanb 0.42 (0.36, –0.54 to 1) 0.57 (0.26, 0.08–1) 0.47 (0.35, –0.18 to 1) 0.920 0.972
EQ-VASf Meanb 61.2 (19.1, 10–100) 67.8 (18, 50–100) 65.2 (14.9, 40–90) 0.881 0.622
BMI, body mass index; EQ, EuroQuol; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LVSD, left ventricular systolic dysfunction; MMSE. Mini Mental State
Examination; VAS, visual analogue scale.
aFor tabulation purposes, three cases of LVSD without clinical signs of heart failure are included
bMean, standard deviation, range
cResidential homes are registered to provide personal and social care for people no longer able to live independently; nursing homes provide these services in addition to medical
and nursing care; nursing homes additionally include specialist mental healthcare. Some facilities provide a mixture of levels of care.
dA score of ≤23 required study consent by ‘consultee declaration’.
eBMI available for 384 (96%) residents.
fVAS score available for 120 (30%) residents.
gFisher’s exact test (all other P-values show Pearson x2).
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guidelines for treatment;36,37 this is borne out in the latest ESC
guidelines.38
Implications of study findings
The findings of this study have implications for practice internation-
ally and challenge the current focus on diagnosis and treatment of
undifferentiated HF in this population: high levels of misdiagnosis,
missed diagnosis, and the lack of evidence-based treatment found
in this study might be explained in part by this lack of differenti-
ation. In this study, HF was diagnosed in almost a quarter
(22.8%) of participants. The prevalence of LVSD was lower than
anticipated, while rates of asymptomatic LVSD reflect international
data.20 However, the study found high rates of HFpEF: this is the
first known prevalence study to report HFpEF and LVSD as
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Heart failure-related characteristics of participants by (study-determined) heart failure status
No HF (A), n 5 308 LVSD (B), n 5 34 HFpEF (C), n5 57 P-value (A vs. B) P-value (A vs. C)
Symptoms
Orthopnea 36 (11.7%) 10 (29.4%) 17 (29.8%) 0.027a 0.003
Signs and echo findings
Raised JVPb 25 (8.1%) 7 (20.6%) 10 (17.5%) 0.054a 0.058
Lung cracklesc 52 (16.9%) 12 (35.3%) 19 (33.3%) 0.031a 0.012
Oedemad 125 (40.6%) 19 (55.9%) 39 (68.4%) 0.487 0.001
Systolic BPe 131 (+22) 131 (+26) 135 (+25) 0.896 0.141
Diastolic BPf 72 (+10) 71 (+13) 68 (+10) 0.213 0.643
Heart rate 72 (+12) 75 (+13) 74 (+13) 0.630 0.541
Respiratory rateg 18 (+4) 19 (+4) 18 (+4) 0.293 0.374
Abnormal ECG 153 (49.7%) 29 (85.3%) 35 (61.4%) ,0.001 0.157
Abnormal diastolic function 85 (27.6%) 14 (41.2%) 56 (98.2%) 0.334 ,0.001
Ejection fraction %h 63.9 (+8.0) 39.0 (+7.1) 56.0 (+2.2) 0.191 0.825
Severe aortic regurgitationi 0 (0%) 0 (0%) 0 (0%)
Severe aortic stenosis 3 (1.0%) 2 (5.9%) 2 (3.5%) 0.113a 0.263a
Severe mitral regurgitationj 2 (0.6%) 1 (2.9%) 1 (1.8%) ,0.001 0.004
Severe mitral stenosisk 0 (0%) 0 (0%) 1 (1.8%) 0.001
BP, blood pressure; ECG, electorcardiogram; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; JVP, jugular venous presure; LVSD, left ventricular systolic
dysfunction.
aFisher’s exact test (all other P-values show Pearson x2).
bJVP measurement was available for 384 (96.2%) residents.
cLung assessment was available for 398 (99.7%) residents.
dOedema assessment was available for 397 (99.4%) residents.
eSystolic BP measurement was available for 398 (99.7%) residents.
fDiastolic BP measurement was available for 395 (98.9%) residents.
gRespiratory rate was available for 398 (99.7%) residents.
hEjection fraction % was available for 17 (4%) residents.
iAortic regurgitation measurement was available for 366 (91.7%) residents.
jMitral regurgitation measurement was available for 385 (96.5%) residents.
kMitral stenosis measurement was available for 396 (99.2%) residents. All other measurements were available for the full cohort (n ¼ 399).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Comparison of study findings from medical and health care records
Study General practice notes General practice HF register Care facility notes
LVSD (n ¼ 34) Confirmeda 15 (44.1%) 16 (47.1%) 4 (11.8%)
Newb 19 (55.9%) 18 (52.9%) 30 (88.2%)
Not confirmedc 24 47 13
HFpEF (n ¼ 57) Confirmed 3 (5.3%) 6 (10.5%) 3 (5.3%)
New 54 (94.7%) 51 (89.5%) 54 (94.7%)
Not confirmed 36 57 14
HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LVSD, left ventricular systolic dysfunction.
aStudy finding and health record agree.
bLVSD found in study but not in health record.
cLVSD found in health record but not confirmed by study.
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clearly defined subgroupings of HF in this population. Half of the
HF cases diagnosed within the study were previously undiagnosed,
while three-quarters of previously recorded cases appeared mis-
diagnosed (not confirmed by the study). Baseline demographic
characteristics of participants and non-participants were almost
identical and reflect other long-term care populations in different
socio-economic groups and different countries with alternative
service provision models.18,24,34,35 Findings are therefore likely to
be generalizable nationally and internationally. The cohort did
not include patients from ethnic minorities; these patients are
much less commonly represented in care home populations for
cultural reasons. Half of study-determined cases of LVSD (17 of
34) and 6 of 57 cases of HFpEF were previously recorded as undif-
ferentiated HF in general practice records. Previous studies have
limited their examination of care provision to records held by
healthcare professionals outside of long-term care facilities. Our
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Co-morbidities and drug prescriptions by study-determined heart failure status
Characteristics No HF (A), n5 308 LVSD (B), n5 34 HFpEF (C), n5 57 P-value (A vs. B) P-value (A vs. C)
Co-morbidities
Myocardial infarction 21 (6.8%) 7 (20.6%) 4 (7.0%) 0.012* 0.507*
Ischaemic heart disease 54 (17.5%) 6 (17.6%) 14 (24.6%) 0.549* 0.143*
Hypertension 151 (49.0%) 16 (47.1%) 26 (45.6%) 0.508* 0.380*
Atrial fibrillation 45 (14.6%) 14 (41.2%) 8 (14.0%) ,0.001* 0.351*
Valvular heart disease 9 (2.9%) 4 (11.8%) 3 (5.3%) 0.127* 0.364*
Mitral valvular heart disease 5 (1.6%) 1 (2.9%) 2 (3.5%) 0.513* 0.320*
Aortic valvular heart disease 5 (1.6%) 1 (2.9%) 2 (3.5%) 0.513* 0.320*
Diabetes 59 (19.2%) 7 (20.6%) 9 (15.8%) 0.464* 0.337*
COPD 25 (8.1%) 4 (11.8%) 11 (19.3%) 0.451* 0.016*
Osteoarthritis 105 (34.1%) 15 (44.1%) 22 (38.6%) 0.184* 0.355*
Cognitive impairment 102 (33.1%) 10 (29.4%) 9 (15.8%) 0.538* 0.006*
Prescribed drugs
Beta-blocker 56 (18.2%) 16 (47.1%) 11 (19.3%) ,0.001* 0.460*
ACE inhibitor 58 (18.8%) 15 (44.1%) 15 (26.3%) 0.021 0.939
Angiotensin receptor blocker 18 (5.8%) 1 (2.9%) 5 (8.8%) 0.373* 0.248*
Calcium chanel blocker 56 (18.2%) 5 (14.7%) 17 (29.8%) 0.313* 0.030*
Diuretic 85 (27.6%) 19 (55.9%) 24 (42.1%) 0.002* 0.057*
Statin 117 (38.0%) 17 (50.0%) 27 (47.4%) 0.155* 0.154*
Digoxin 24 (7.8%) 5 (14.7%) 2 (3.5%) 0.111* 0.150*
Antiplatelet 159 (51.6%) 24 (70.6%) 24 (42.1%) 0.215* 0.099*
Spironolactone 7 (2.3%) 0 (0%) 1 (1.8%) 0.487* 0.680*
Bronchodilators 46 (14.9%) 7 (20.6%) 16 (28.1%) 0.370* 0.020*
Warfarin 8 (2.6%) 4 (11.8%) 1 (1.8%) 0.018* 0.423*
NSAIDs 25 (8.1%) 1 (2.9%) 7 (12.3%) 0.203* 0.174*
ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LVSD, left ventricular
systolic dysfunction; NSAIDs, non-steroidal anti-inflammatory drugs.
*Fisher’s Exact Test (all other p values show Pearson Chi-Square).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 6 Rates of angiotensin-converting enzyme, beta-blocker, and spironolactone prescribing in patients with left
ventricular systolic dysfunction, categorized by study findings
Study Any HF recorda ACE inhibitorb Beta-blockersb Spironolactoneb
LVSD (n ¼ 34) Confirmed 19 10 (53%) 11 (58%) 0 (0%)
New 15 5 (33%) 5 (33%) 0 (0%)
Not confirmed 61 19 (31%) 23 (38%) 3 (5%)
ACE, angiotensin-converting enzyme; HF, heart failure; LVSD, left ventricular systolic dysfunction.
aA heart failure record, specified or unspecified in general practice notes, register, or care facility records.
bAny dose.
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study supports international evidence that an accurate diagnosis
may be missed in up to half of cases.18,21–23 Difficulties diagnosing
HF, organizing care across a wide range of care facilities, and allo-
cating scarce health service resources can mean that important
health needs of the older population in care are unmet. Based
on these data, a review of current diagnostic processes within
long-term care seems timely.
Strengths and limitations
Long-term care facilities proved a challenging environment, which
led to some limitations for this research. As a condition of research
access into care facilities, staff determined in part which residents
were invited to participate. Thus participation within the study was
filtered at three levels, by staff, by relatives, and by the residents
themselves. Limited cognitive capacity was common, and a consult-
ee declaration was required in 66% of participants. While 35% of
eligible (non-excluded) residents participated, individual reasons
for non-participation could not be determined within the selection
process. A comparison of participants and non-participants reveals
similarity in age, gender, and ethnicity. Study assessment tools,
including the AMTS and EQ-5D, were carefully selected to avoid
lengthy assessment times. A very high proportion (399/405,
98.5%) of recruited participants completed assessments, pointing
to the acceptability of the assessments, including portable echocar-
diography, and the generalizability of findings.
There were difficulties assessing NYHA class and other symp-
toms and signs in this sedentary population; the lack of correlation
between NYHA classification and LVSD severity, and between
LVSD and HFpEF raises questions about its utility in the study
population. Symptoms suggestive of HF such as oedema and dys-
pnoea were poor predictors of HF in this study. These were as
common in participants without HF as in those with HF, and
appear to have little diagnostic utility in this population. The
routine introduction of portable echocardiography in care facilities
might be essential to accurate diagnosis; this reflects the views of
others about how best to achieve accurate diagnosis in older
people.12
This study examined long-term care facility records which are
used on a day to day basis (including prescriptions and co-
morbidities) for this group and found them to be incomplete.
Access to general practice and care facility records provided infor-
mation about diagnoses and treatment but not the rationale behind
decisions or relevant contraindications to medications; thus, the
reasons for treatment decisions remain unknown.
Conclusion
In our large study of older people in long-term care, HF was diag-
nosed in almost a quarter of residents, two-thirds of whom had
HFpEF. The prevalence of HF was substantially higher than in com-
munity populations. Symptoms and signs typically associated with
HF such as leg oedema and breathlessness appear to have little
clinical utility in this population. Findings suggest that this popula-
tion is not routinely receiving evidence-based diagnosis; screening
for HF was feasible and acceptable in this study. This challenges the
current organization of diagnostic services for older people in care,
which needs to be addressed at national and international levels.
Funding
This paper presents independent research funded by the National
Institute for Health Research (NIHR) under its Research for
Patient Benefit (RfPB) Programme (Grant Reference Number
PB-PG-0407-13309). The views expressed are those of the
authors and not necessarily those of the NHS, the NIHR or the
Department of Health.
Acknowledgements
The authors wish to thank Mrs Rebecca Maier and Miss Jennifer
Wilkinson of the Durham Clinical Trials Unit for their roles in
overseeing research governance processes and data management.
We thank Dr Novin Manshani, Dr David Hodges, and Ms Jan
Hart for their roles in study conduct.
Conflict of interest: None declared.
References
1. Aronow WS. Clinical causes of death of 2372 older persons in a nursing home
during 15-year follow-up. J Am Med Dir Assoc 2000;1:95–96.
2. Gambassi G, Forman DE, Lapane KL, Mor V, Sgadari A, Lipsitz LA, Bernabei R.
The SAGE Study Group. Management of heart failure among very old persons
living in long-term care: has the voice of trials spread. Am Heart J 2000;139:85–93.
3. Ahmed A, Weaver M, Allman RM, DeLong JF, Aronow WS. The quality of care of
nursing home residents hospitalized with heart failure. J Am Geriatr Soc 2002;50:
1831–1836.
4. Sloane PD, Gruber-Baldini AL, Zimmerman S, Roth M, Watson L, Boustani M,
Magaziner J, Hebel JR. Medication undertreatment in assisted living settings.
Arch Intern Med 2004;164:2031–2037.
5. Shah SM, Carey IM, Harris T, DeWilde S, Cook DG. Quality of chronic disease
care for older people in care homes and the community on a primary care pay
for performance system: retrospective study. BMJ 2001;342:d912.
6. Fried LP. Establishing benchmarks for quality care for an aging population: caring
for vulnerable older adults. Ann Intern Med 2003;139:784–786.
7. Arroll B, Doughty R, Andersen V. Investigation and management of congestive
heart failure. BMJ 2010;341:c3657.
8. Ahmed A, Jones L, Hays CI. DEFEAT Heart Failure: assessment and management
of heart failure in nursing homes made easy. J Am Med Dir Assoc 2008;9:
383–389.
9. Bowman C, Whistler J, Ellerby MA. National census of care home residents. Age
Ageing 2004;33:561–566.
10. Gure TR, Kabeto MU, Blaum CS, Langa KM. Degree of disability and patterns of
caregiving among older Americans with congestive heart failure. J Gen Intern Med
2008;23:70–76.
11. Oudejans I, Mosterd A, Bloemen JA, Valk MJ, van Velzen E, Wielders JP,
Zuithoff NP, Rutten FH, Hoes AW. Clinical evaluation of geriatric outpatients
with suspected heart failure: value of symptoms, signs, and additional tests. Eur
J Heart Fail 2011;13:518–527.
12. Manzano L, Escobar C, Cleland JG, Flather M. Diagnosis of elderly patients with
heart failure. Eur J Heart Fail 2012;14:1097–1103.
13. Mogensen UM, Ersbøll M, Andersen M, Andersson C, Hassager C,
Torp-Pedersen C, Gustafsson F, Køber L. Clinical characteristics and major co-
morbidities in heart failure patients more than 85 years of age compared with
younger age groups. Eur J Heart Fail 2011;13:1216–1223.
14. Fuat A, Hungin A, Murphy J. Barriers to accurate diagnosis and effective
management of heart failure in primary care: qualitative study. BMJ 2003;326:
196–200.
15. Rutten FH, Grobbe DE, Hoes AW. Differences between general practitioners and
cardiologists in diagnosis and management of heart failure: a survey in every-day
practice. Eur J Heart Fail 2003;5:337–344.
16. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA,
Sutton GC. Value of natriuretic peptides in assessment of patients with possible
new heart failure in primary care. Lancet 1997;350:1349–1353.
17. Aronow WS, Rich MW, Goodlin SJ, Birkner T, Zhang Y, Feller MA, Aban IB,
Jones LG, Bearden DM, Allman RM, Ahmed A. In-hospital cardiology consultation
and evidence-based care for nursing home residents with heart failure. J Am Med
Dir Assoc 2012;13:448–52.
H.C. Hancock et al.164
 at D
urham
 U
niversity on January 23, 2013
http://eurjhf.oxfordjournals.org/
D
ow
nloaded from
 
18. Barents M, van der Horst I, Voors A, Hillege J, Muskiet F, de Jongste M. Prevalence
and misdiagnosis of chronic heart failure in nursing home residents: the role of
B-type natruiretic peptides. Neth Heart J 2008;16:123–128.
19. Paulus WJ, Tschope T, Sanderson JE, Paulus WJ, Tscho¨pe C, Sanderson JE,
Rusconi C, Flachskampf F, Rademakers FE, Marino P, Smiseth O, De
Keulenaer G, Leite-Moreira AF, Borbe´ly A, E´des I, Handoko ML, Heymans S,
Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose dia-
stolic heart failure: a consensus statement on the diagnosis of heart failure with
normal left ventricular ejection fraction by the Heart Failure and Echocardiog-
raphy Associations of the European Society of Cardiology. Eur Heart J 2007;28:
2539–2550.
20. Mureddu GF, Agabiti N, Rizzello V, Forastiere F, Latini R, Cesaroni G, Masson S,
Cacciatore G, Colivicchi F, Uguccioni M, Perucci CA, Boccanelli A; on behalf of
the PREDICTOR Study Group. Prevalence of preclinical and clinical heart
failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail
2012;14:718–729.
21. Khand A, Shaw M, Gemmel I, Cleland J. Do discharge codes underestimate hos-
pitalisation due to heart failure? Validation study of hospital discharge coding for
heart failure. Eur J Heart Fail 2005;7:792–797.
22. Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, Wosornu D,
Lancashire RJ. Prevalence of left ventricular systolic dysfunction and heart
failure in the Echocardiographic Heart of England Screening study: a population
based study. Lancet 2001;358:439–444.
23. Rutten FH, Cramer MM, Grobbe DE, Rutten FH, Cramer MM, Grobbee1 DE,
Sachs APE, Kirkels JH, Lammers JJ, Hoes AW. Unrecognised heart failure in
elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J
2005;26:1887–1894.
24. Valle R, Chinellato M, Gallo G, Milani L. Heart failure in nursing homes: preva-
lence, hospitalization, compliance to guidelines. Ital Heart J Suppl 2001;2:772–774.
25. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P,
Poole-Wilson PA, Stro¨mberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A,
Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice
Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008. Eur J Heart Fail 2008;10:933–989.
26. Rusinaru D, Leborgne L, Peltier M, Tribouilloy C. Effect of atrial fibrillation on
long-term survival in patients hospitalised for heart failure with preserved ejection
fraction. Eur J Heart Fail 2008;10:566–572.
27. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in
prevalence and outcome of heart failure with preserved ejection fraction. N Engl
J Med 2006;355:251–259.
28. Jong P, McKelvie R, Yusuf S. Should treatment for heart failure with preserved
ejection fraction differ from that for heart failure with reduced ejection fraction?
BMJ 2010;341:c4202.
29. Folstein MF, Folstein SE, McHugh PR, Mini-Mental State. A practical method for
grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
30. Hodkinson HM. Evaluation of a mental test score for assessment of mental im-
pairment in the elderly. Age Ageing 1972;1:233–238.
31. Oppe M, Szende A, de Charro F. Comparative review of visual analogue scale
value sets. In: Szende A, Oppe M, Devlin N, eds. EQ-5D Value Sets: Inventory, Com-
parative Review and User Guide, Vol. 2. EuroQoL Group Monographs. The Neth-
erlands: Springer; 2007.
32. Masani N, Wharton G, Allen J, Chambers J, Graham J, Jones R, Rana B, Steeds R.
Echocardiography: Guidelines for Valve Quantification. British Society of Echocardiog-
raphy Education Committee. http://www.bsecho.org/media/40492/echo-
pocket_a6_2011__3_.pdf (April 2009).
33. Lang R, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH,
Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St. John Sutton M,
Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr
2006;7:79e108.
34. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart
failure in older African-Americans, Hispanics, and Whites. Am J Cardiol 1999;84:
611–612.
35. Valle R, Apsromonte N, Barro S, Canali C, Carbonieri E, Ceci V, Chinellato M,
Gallo G, Giovinazzo P, Ricci R, Milani. The NT-proBNP assay identifies very
elderly nursing home residents suffering from pre-clinical heart failure. Eur
J Heart Fail 2005;7:542–551.
36. Fu M, Zhau J, Sun A, Zhang S, Zhang C, Zou Y, Fu M, Ge J. Efficacy of ACE inhi-
bitors in chronic heart failure with preserved ejection fraction. A meta analysis of
7 prospective clinical studies. Int J Cardiol 2012;155:33–38.
37. Udelson JE. Heart failure with preserved ejection fraction. Circulation 2011;124:
e540–e543.
38. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Boehm M, Dickstein K,
Falk V, Filippatos G, Fonseca C, Sanchez MAG, Jaarsma T, Kober L, Lip GYH,
Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Roennevik PK,
Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA,
Zannad F, Zeiher A. The Task Force for the Diagnosis and Treatment of Acute
and Chronic Heart Failure 2012 of the European Society of Cardiology. Devel-
oped in collaboration with the Heart Failure Association (HFA) of the ESC.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure 2012. Eur J Heart Fail 2012; 14:803–869.
Heart failure in long-term care 165
 at D
urham
 U
niversity on January 23, 2013
http://eurjhf.oxfordjournals.org/
D
ow
nloaded from
 
